About Mercury Therapeutics, Inc. (http://www.mtipharm.com)
MTI is an early stage drug discovery company focusing on the development of small molecule candidates against a number of selected protein kinase drug targets in metabolic diseases and oncology. MTI's main focus is on the discovery and development of orally active small molecule activators of AMPK, a well-validated though largely unexploited, protein kinase drug target in metabolic disease. While a number of anti-diabetic drugs currently on the market, including metformin (Glucophage(R)) and pioglitazone (Actos(R)), act indirectly to activate AMPK, MTI is seeking to develop the first orally available direct AMPK activator. The potential indications of a successful AMPK targeted drug include Type-2 diabetes, hyperlipidemia, obesity, metabolic syndrome and endocrine cancers.
MTI was launched in 2001, and has an exclusive license to a patent from
Dartmouth College and St. Vincent's Institute for Biomedical Research in
Melbourne, Australia for AMP activated protein kinase (AMPK). In June 2001,
MTI launched its R&D operations following execution of a collaboration
agreement with Aventis, AG to develop AMPK activators to treat Type-2
diabetes and obesity. In June 2004, Aventis was acquired by Sanofi, and MTI
re-acquired all of its intellectual property rights to AMP kinase as well
as the rights to develop compounds identified during the collaboration. In
October, 2004: MTI secured external financing from XL TechGroup, Inc. In Q4
2005, MTI demonstrated its first preclinical proof-of-principle of active
compounds in a glucose tolerance test in mice.
|SOURCE Mercury Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved